Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 versus placebo in very preterm and growth-restricted infants
NL-OMON59905Phase 3Not yet recruiting
- Sponsor
- Elgan Pharma
- Start
- Mar 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intestinal malabsorption comparing ELGN-2112 with Placebo (2 arms). Primary endpoints: Adverse events and adverse drug reactions, Blood glucose and 2 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on NL-OMON59905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59905.